GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (NAS:GMAB) » Definitions » Cyclically Adjusted PS Ratio

Genmab A/S (Genmab A/S) Cyclically Adjusted PS Ratio : 18.04 (As of Apr. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Genmab A/S's current share price is $28.15. Genmab A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.56. Genmab A/S's Cyclically Adjusted PS Ratio for today is 18.04.

The historical rank and industry rank for Genmab A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

GMAB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 18.04   Med: 51.08   Max: 72.33
Current: 18.53

During the past years, Genmab A/S's highest Cyclically Adjusted PS Ratio was 72.33. The lowest was 18.04. And the median was 51.08.

GMAB's Cyclically Adjusted PS Ratio is ranked worse than
82.77% of 505 companies
in the Biotechnology industry
Industry Median: 5.24 vs GMAB: 18.53

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genmab A/S's adjusted revenue per share data for the three months ended in Dec. 2023 was $1.036. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.56 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Genmab A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Cyclically Adjusted PS Ratio Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.44 58.20 47.27 36.10 20.43

Genmab A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.10 29.96 28.10 25.22 20.43

Competitive Comparison of Genmab A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Genmab A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Cyclically Adjusted PS Ratio falls into.



Genmab A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Genmab A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=28.15/1.56
=18.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Genmab A/S's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.036/116.7000*116.7000
=1.036

Current CPI (Dec. 2023) = 116.7000.

Genmab A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.082 99.600 0.096
201406 0.037 99.700 0.043
201409 0.082 99.700 0.096
201412 0.062 99.400 0.073
201503 0.026 100.200 0.030
201506 0.043 100.300 0.050
201509 0.069 100.200 0.080
201512 0.141 99.800 0.165
201603 0.042 100.200 0.049
201606 0.086 100.600 0.100
201609 0.089 100.200 0.104
201612 0.212 100.300 0.247
201703 0.058 101.200 0.067
201706 0.188 101.200 0.217
201709 0.082 101.800 0.094
201712 0.260 101.300 0.300
201803 0.182 101.700 0.209
201806 0.129 102.300 0.147
201809 0.151 102.400 0.172
201812 0.303 102.100 0.346
201903 0.145 102.900 0.164
201906 0.186 102.900 0.211
201909 0.237 102.900 0.269
201912 0.669 102.900 0.759
202003 0.200 103.300 0.226
202006 1.251 103.200 1.415
202009 0.414 103.500 0.467
202012 0.506 103.400 0.571
202103 0.383 104.300 0.429
202106 0.484 105.000 0.538
202109 0.553 105.800 0.610
202112 0.587 106.600 0.643
202203 0.476 109.900 0.505
202206 0.681 113.600 0.700
202209 0.825 116.400 0.827
202212 1.107 115.900 1.115
202303 0.622 117.300 0.619
202306 0.928 116.400 0.930
202309 1.031 117.400 1.025
202312 1.036 116.700 1.036

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab A/S  (NAS:GMAB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Genmab A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (Genmab A/S) Business Description

Industry
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (Genmab A/S) Headlines

From GuruFocus

Top 5 2nd Quarter Trades of Lester Murray Antman dba SimplyRich

By GuruFocus Research GuruFocus Editor 07-22-2022